| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | AZD0530 | FIMM | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |